Immune characterization of metastatic colorectal cancer patients post reovirus administration

BACKGROUND: KRAS mutations are prevalent in 40–45% of patients with colorectal cancer (CRC) and targeting this gene has remained elusive. Viruses are well known immune sensitizing agents. The therapeutic efficacy of oncolytic reovirus in combination with chemotherapy is examined in a phase 1 study o...

Descripción completa

Detalles Bibliográficos
Autores principales: Parakrama, Ruwan, Fogel, Elisha, Chandy, Carol, Augustine, Titto, Coffey, Matt, Tesfa, Lydia, Goel, Sanjay, Maitra, Radhashree
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301987/
https://www.ncbi.nlm.nih.gov/pubmed/32552875
http://dx.doi.org/10.1186/s12885-020-07038-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301987/
https://www.ncbi.nlm.nih.gov/pubmed/32552875
http://dx.doi.org/10.1186/s12885-020-07038-2

Ejemplares similares